Compare Adaptive Biotechnologies Corp (ADPT) vs Electronic Arts Inc. (EA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Electronic Arts Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $19.99 (market cap $3.33B), while Electronic Arts Inc. trades at $205.36 (market cap $51.51B). The key difference: Electronic Arts Inc. is far larger — about 15.5× Adaptive Biotechnologies Corp's market cap, and Electronic Arts Inc. pays a 0.37% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | EA | |
|---|---|---|
Market Cap | $3.33B | $51.51B |
Sector | Health | Technology |
52-Week High | $22.37 | $205.45 |
52-Week Low | $10.24 | $147.79 |
Enterprise Value | $3.19B | $50.08B |
Dividend Yield | — | 0.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Electronic Arts (EA) trades at $205.44, up 0.11% on the day, with a bullish technical signal from moving averages and strong profitability metrics including a 78.97% gross margin. Recent news highlights a potential $55 billion acquisition by Saudi investors pending EU approval and the launch of new gaming titles and an advertising platform, indicating active business development.
The stock presents a mixed outlook with high valuation ratios (P/E of 58.46) posing a risk, but analyst consensus leans positive with no sell ratings. Key risks include earnings volatility, as seen in recent misses, and regulatory scrutiny over the acquisition. Upside potential hinges on successful game launches and the advertising initiative driving future growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Electronic Arts Inc.
EA is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, FIFA, Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.
Read more on EA →
